RA
PCVX icon

Rise Advisors’s Vaxcyte PCVX Stock Holding History

Rise Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-262
Closed -$9.44K – 1056
2025
Q3 		$9.44K Hold
262
– – ﹤0.01% 1019
2025
Q2 		$8.52K Hold
262
– – ﹤0.01% 1064
2025
Q1 		$9.89K Buy
262
+33
+14% +$2.64K ﹤0.01% 974
2024
Q4 		$18.7K Hold
229
– – 0.01% 704
2024
Q3 		$26.2K Hold
229
– – 0.01% 493
2024
Q2 		$17.3K Hold
229
– – 0.01% 723
2024
Q1 		$15.6K Buy
+229
New +$15.9K 0.01% 833

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rise Advisors's PCVX Position: Q4 2025 in Review

Rise Advisors sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 262 shares — an estimated $9.44K sold.

Rise Advisors first reported a position in PCVX in Q1 2024 and held it in 7 quarters. The position peaked at $26.2K in Q3 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Rise Advisors reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 262 Vaxcyte shares in Q4 2025, an estimated $9.44K.
  • Rise Advisors first reported a position in Vaxcyte in Q1 2024 and held it in 7 quarters.
  • Rise Advisors's Vaxcyte position peaked at $26.2K in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.